Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
Chronic myeloid leukaemia (CML) is currently treated with inhibitors of the CML specific oncoprotein, bcr-abl. While this strategy is initially successful, drug resistance can become a problem. Therefore, new targets need to be identified to ensure the disease can be appropriately managed. The thior...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Buch |
| Veröffentlicht: |
MDPI AG,
2020-03-01T00:00:00Z.
|
| Schlagworte: | |
| Online-Zugang: | Connect to this object online. |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Online
Connect to this object online.3rd Floor Main Library
| Signatur: |
A1234.567 |
|---|---|
| Exemplar 1 | Verfügbar |